Welcome to our dedicated page for Citius Pharmaceuticals news (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals stock.
Citius Pharmaceuticals reports developments across its critical care and targeted oncology business, including activity at majority-owned subsidiary Citius Oncology. The company’s recurring updates center on LYMPHIR (denileukin diftitox-cxdl), an engineered IL-2 diphtheria toxin fusion protein approved for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy.
Company news also covers LYMPHIR commercialization, U.S. launch progress, international access through Named Patient Programs, and investigator-initiated oncology studies involving gynecologic cancers and diffuse large B-cell lymphoma. Capital updates include registered direct offerings, warrant issuances, non-dilutive funding and other financing actions that support product commercialization and development programs.
Citius Pharmaceuticals announced positive topline results from its Phase 3 clinical trial of Mino-Lok, an antibiotic lock solution for catheter-associated infections. The trial achieved its primary endpoint with a statistically significant improvement in time to catheter failure (p=0.0006). Secondary endpoints showed a higher percentage of patients retaining their catheters compared to the control arm (p=0.0025). The study involved 241 patients and demonstrated Mino-Lok's efficacy and safety. The company plans to engage with the FDA for further development.
Citius Pharmaceuticals (CTXR) reported its fiscal Q2 2024 financial results and provided a business update. Key highlights include:
- The FDA accepted LYMPHIR's BLA with a PDUFA target date of Aug 13, 2024.
- Topline results for Mino-Lok’s Phase 3 trial expected in Q2 2024.
- Continued engagement with FDA for Halo-Lido’s development.
- Merger with TenX Keane Acquisition progressing, awaiting SEC and TENK shareholder approval.
- Completed a $15M direct offering in April 2024, extending cash runway to Dec 2024.
Financial highlights:
- $12.6M in cash as of Mar 31, 2024.
- R&D expenses decreased to $3.6M from $4.7M YoY; G&A expenses slightly decreased to $4.3M from $4.8M YoY.
- Net loss improved to $8.5M, $0.05 per share, from $10.5M, $0.07 per share YoY.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) will participate in the upcoming EF Hutton and H.C. Wainwright investor conferences. CEO Leonard Mazur will host one-on-one investor meetings at the EF Hutton Annual Global Conference on May 15, 2024, and present at the H.C. Wainwright BioConnect Investor Conference on May 20, 2024.
Citius Pharmaceuticals Inc. (Nasdaq: CTXR) closed a registered direct offering, raising $15 million through the sale of 21,428,574 shares and warrants. The offering was facilitated by H.C. Wainwright & Co. The company plans to utilize the funds for general corporate purposes, including product development and working capital.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.